Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Montalescot

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Circulation|October 13, 2004
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromesJ P Collet, G Montalescot, B Blanchet, et al.
Annales De Cardiologie Et D'Angeiologie|January 13, 2004
[FACT: French national registry of acute coronary syndromes. Specific study of French general hospital centers]J J Dujardin, P G Steg, J Puel, et al.
International Journal of Cardiology|September 12, 2020
Unusual arterial thrombotic events in Covid-19 patientsC de Roquetaillade, B G Chousterman, D Tomasoni, et al.
The American Journal of Cardiology|August 18, 2000
Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarctionR Choussat, G Montalescot, J Collet, et al.
The New England Journal of Medicine|June 23, 2001
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarctionG Montalescot, P Barragan, O Wittenberg, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 19, 2006
Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosisJ P Collet, Y Allali, C Lesty, et al.
Thrombosis and Haemostasis|April 21, 2011
Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. The AERER studyG Cayla, P Sié, J Silvain, et al.
Journal of the American College of Cardiology|June 23, 2001
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary interventionK M Anderson, R M Califf, G W Stone, et al.
European Journal of Neurology|May 29, 2009
High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH RegistryF T Aichner, R Topakian, M J Alberts, et al.
Circulation|August 26, 1998
Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE TrialG Montalescot, F Philippe, A Ankri, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Circulation|October 13, 2004
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromesJ P Collet, G Montalescot, B Blanchet, et al.
Annales De Cardiologie Et D'Angeiologie|January 13, 2004
[FACT: French national registry of acute coronary syndromes. Specific study of French general hospital centers]J J Dujardin, P G Steg, J Puel, et al.
International Journal of Cardiology|September 12, 2020
Unusual arterial thrombotic events in Covid-19 patientsC de Roquetaillade, B G Chousterman, D Tomasoni, et al.
The American Journal of Cardiology|August 18, 2000
Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarctionR Choussat, G Montalescot, J Collet, et al.
The New England Journal of Medicine|June 23, 2001
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarctionG Montalescot, P Barragan, O Wittenberg, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 19, 2006
Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosisJ P Collet, Y Allali, C Lesty, et al.
Thrombosis and Haemostasis|April 21, 2011
Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. The AERER studyG Cayla, P Sié, J Silvain, et al.
Journal of the American College of Cardiology|June 23, 2001
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary interventionK M Anderson, R M Califf, G W Stone, et al.
European Journal of Neurology|May 29, 2009
High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH RegistryF T Aichner, R Topakian, M J Alberts, et al.
Circulation|August 26, 1998
Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE TrialG Montalescot, F Philippe, A Ankri, et al.
Pageof 15